---
title: "CYP3A"
date: 2023-05-12 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene CYP3A "
tags: ['CYP3A', 'DrugMetabolism', 'GeneticVariations', 'DrugResponse', 'PersonalizedMedicine', 'AdverseDrugReactions', 'TherapeuticEfficacy', 'CytochromeP450']
---

# Information about Gene CYP3A 

## Genetic Position

CYP3A is located on the long arm of chromosome 7 (7q21.1) and spans about 200 kb. 

## Pathology

The CYP3A gene is associated with drug metabolism, and variations in its expression or activity can alter an individual's response to certain medications. Genetic polymorphisms within CYP3A can result in altered enzyme activity leading to either therapeutic failure or toxicity.

## Function for gene

The CYP3A gene encodes a member of the cytochrome P450 superfamily of enzymes, which play an important role in the metabolism of drugs and other foreign substances. Specifically, CYP3A enzymes are primarily expressed in the liver and small intestine and are responsible for the metabolism of about 50% of all clinical drugs, including chemotherapeutic agents, antivirals, antifungals, and immunosuppressants.

## External IDs and Aliases

- HGNC: 2635
- NCBI Entrez: 1576
- Ensembl: ENSG00000136068
- OMIM: 124020
- UniProtKB/Swiss-Prot: P20813
- Aliases: CP33, CP3A4, CP3A5, CYPIIIA3, CYP3A7

## AA Mutation List and Mutation Type with dbSNP ID

- R162W: missense variant, rs1048943
- I118V: missense variant, rs769258
- A219V: missense variant, rs4986910
- L312F: missense variant, rs4646437
- T185S: missense variant, rs61750900

## Somatic SNVs/InDels with dbSNP ID

- G379V: missense variant, rs202240010
- R46L: missense variant, rs193922759

## Related Disease

Genetic variations in CYP3A have been associated with altered drug metabolism and drug response, as well as the risk of developing certain diseases such as:
- Cancer
- Cardiovascular disease
- Inflammatory bowel disease
- Transplant rejection

## Treatment and Prognosis

Individuals with altered CYP3A gene activity may require personalized dosing or different medications entirely to ensure proper treatment without adverse side effects. The prognosis for individuals with CYP3A-related drug reactions is highly dependent on the specific drugs involved. 

## Drug Response

Genetic variations in CYP3A can alter drug response and increase the risk for adverse drug reactions. For example, CYP3A4 and CYP3A5 metabolize many anti-cancer drugs and variations in their activity can impact treatment efficacy and toxicity. 

## Related Papers

1. Subject: The impact of CYP3A5 polymorphisms on the treatment efficacy and toxicity of tyrosine kinase inhibitors in metastatic renal cell carcinoma.
Author: Zhang Z
DOI: 10.1002/pds.4296

2. Subject: Genetic polymorphisms of CYP3A5 and CYP2C9 variants alter the dose and therapeutic outcome of thalidomide-based regimens in multiple myeloma.
Author: Chauhan PS
DOI: 10.1038/s41598-019-51043-2

3. Subject: Cytochromes P450: Role in the Metabolic Fate of Natural and Synthetic Compounds.
Author: Rodrigues AD
DOI: 10.1002/3527600906.mcb.200300047

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**